Triple‑negative breast cancer and its association with obesity (Review)
- Authors:
- Heng Sun
- Jing Zou
- Ling Chen
- Xuyu Zu
- Gebo Wen
- Jing Zhong
-
Affiliations: Institute of Clinical Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China, Department of Neurological Medicine, Hunan Institute of Gerontology, Hunan Geriatric Hospital, Changsha, Hunan 410016, P.R. China - Published online on: September 29, 2017 https://doi.org/10.3892/mco.2017.1429
- Pages: 935-942
This article is mentioned in:
Abstract
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ziegler RG, Anderson WF and Gail MH: Increasing breast cancer incidence in China: The numbers add up. J Natl Cancer Ins. 100:1339–1341. 2008. View Article : Google Scholar | |
|
de Waard F and Baanders-van Halewijn EA: A prospective study in general practice on breast-cancer risk in postmenopausal women. Int J Cancer. 14:153–160. 1974. View Article : Google Scholar : PubMed/NCBI | |
|
Wiseman M: The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: A global perspective. Proc Nutr Soc. 67:pp. 253–256. 2008, View Article : Google Scholar : PubMed/NCBI | |
|
Rakha EA, Elsayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA, et al: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ and Eley JW: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 20:1071–1082. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Vona-Davis L, Rose DP, Hazard H, Howard-McNatt M, Adkins F, Partin J and Hobbs G: Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 17:3319–3324. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cakar B, Muslu U, Erdogan AP, Ozisik M, Ozisik H, Tunakan Dalgic C, Durusoy R, Karaca B, Sezgin C, Karabulut B and Uslu R: The role of body mass index in triple negative breast cancer. Oncol Res Treat. 38:518–522. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mowad R, Chu QD, Li BD, Burton GV, Ampil FL and Kim RH: Does obesity have an effect on outcomes in triple-negative breast cancer? J sur Res. 184:253–259. 2013. View Article : Google Scholar | |
|
Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N and Edge SB: Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. 117:4132–4140. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pierobon M and Frankenfeld CL: Obesity as a risk factor for triple-negative breast cancers: A systematic review and meta-analysis. Breast Cancer Res Treat. 137:307–314. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hao S, Liu Y, Yu KD, Chen S, Yang WT and Shao ZM: Overweight as a prognostic factor for triple-negative breast Cancers in Chinese Women. PLoS One. 10:e01297412015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 16:439–443. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Cook LS, Tang MT, Porter PL, Hill DA, Wiggins CL and Li CI: Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 157:545–554. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL and Anis AH: The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 9:882009. View Article : Google Scholar : PubMed/NCBI | |
|
Gillespie EF, Sorbero ME, Hanauer DA, Sabel MS, Herrmann EJ, Weiser LJ, Jagielski CH and Griggs JJ: Obesity and angiolymphatic invasion in primary breast cancer. Ann Surg Oncol. 17:752–759. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli GB, Brand R, Goldfine ID and Vigneri R: Elevated insulin receptor content in human breast cancer. J Clin Invest. 86:1503–1510. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Ng EH, Gao F, Ji CY, Ho GH and Soo KC: Risk factors for breast carcinoma in Singaporean Chinese women: The role of central obesity. Cancer. 80:725–731. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Sellers TA, Kushi LH, Potter JD, Kaye SA, Nelson CL, McGovern PG and Folsom AR: Effect of family history, body-fat distribution, and reproductive factors on the risk of postmenopausal breast cancer. New Engl J Med. 326:1323–1329. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Sellers TA, Gapstur SM, Potter JD, Kushi LH, Bostick RM and Folsom AR: Association of body fat distribution and family histories of breast and ovarian cancer with risk of postmenopausal breast cancer. Am J Epidemiol. 138:799–803. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 109:123–139. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bao PP, Cai H, Peng P, Gu K, Su Y, Shu XO and Zheng Y: Body mass index and weight change in relation to triple-negative breast cancer survival. Cancer Causes Control. 27:229–236. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K and Mitchell EP: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 110:876–884. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L and Ursin G: Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev. 19:2366–2378. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Phipps AI, Malone KE, Porter PL, Daling JR and Li CI: Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 17:2078–2086. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 339:71–85. 1992.PubMed/NCBI | |
|
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl J Med. 346:1616–1622. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA and Kuperwasser C: Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 67:2062–2071. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Black DM and Solomon E: The search for the familial breast/ovarian cancer gene. Trends Genet. 9:22–26. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Winqvist R, Peltoketo H, Isomaa V, Grzeschik KH, Mannermaa A and Vihko R: The gene for 17 beta-hydroxysteroid dehydrogenase maps to human chromosome 17, bands q12-q21, and shows an RFLP with ScaI. Hum Genet. 85:473–476. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M and Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 95:1482–1485. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Turner N, Tutt A and Ashworth A: Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:pp. 8418–8423. 2003, View Article : Google Scholar : PubMed/NCBI | |
|
Fournier S, Brihmat F, Durand JC, Sterkers N, Martin PM, Kuttenn F and Mauvais-Jarvis P: Estradiol 17 beta-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency. Cancer Res. 45:2895–2899. 1985.PubMed/NCBI | |
|
Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ and De Vivo I: HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev. 13:213–219. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Pisani P: Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem. 114:63–70. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Baserga R, Peruzzi F and Reiss K: The IGF-1 receptor in cancer biology. Int J Cancer. 107:873–877. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Resnik JL, Reichart DB, Huey K, Webster NJ and Seely BL: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 58:1159–1164. 1998.PubMed/NCBI | |
|
Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, et al: Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 65:3781–3787. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R and Moorehead RA: Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 26:1636–1644. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S and Brugge JS: Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 171:1023–1034. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, Gottardis MM, Wong TW, Attar RM, et al: Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol. 27:3165–3175. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yanochko GM and Eckhart W: Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res. 8:R182006. View Article : Google Scholar : PubMed/NCBI | |
|
Davison Z, de Blacquiere GE, Westley BR and May FE: Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: Implications for therapy. Neoplasia. 13:504–515. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, et al: High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 17:2314–2327. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sarfstein R, Maor S, Reizner N, Abramovitch S and Werner H: Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol. 252:241–246. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM and Diamandis EP: Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer. 74:1242–1247. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA and Yee D: Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 88:601–606. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Probst-Hensch NM, Steiner JH, Schraml P, Varga Z, Zürrer-Härdi U, Storz M, Korol D, Fehr MK, Fink D, Pestalozzi BC, et al: IGFBP2 and IGFBP3 protein expressions in human breast cancer: Association with hormonal factors and obesity. Clin Cancer Res. 16:1025–1032. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Martin JL and Baxter RC: Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology. 148:2532–2541. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Martin JL, de Silva HC, Lin MZ, Scott CD and Baxter RC: Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther. 13:316–328. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425–432. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S and Surmacz E: Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: Possible role of obesity-related stimuli. Clin Cancer Res. 12:1447–1453. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Losso JN and Bawadi HA: Hypoxia inducible factor pathways as targets for functional foods. J Agric Food Chem. 53:3751–3768. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Frankenberry KA, Skinner H, Somasundar P, McFadden DW and Vona-Davis LC: Leptin receptor expression and cell signaling in breast cancer. Int J Oncol. 28:985–993. 2006.PubMed/NCBI | |
|
Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM and Sharma D: Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 68:9712–9722. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tsao TS, Lodish HF and Fruebis J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 440:213–221. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 257:79–83. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE and Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 86:1930–1935. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 20:1595–1599. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T, Jamali M, Cooper DR and Yasuda K: Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: Reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta. 1592:107–116. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y and Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 96:1723–1732. 2000.PubMed/NCBI | |
|
Oh SW, Park CY, Lee ES, Yoon YS, Lee ES, Park SS, Kim Y, Sung NJ, Yun YH, Lee KS, et al: Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study. Breast Cancer Res. 13:R342011. View Article : Google Scholar : PubMed/NCBI | |
|
Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK and Roh YK: Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res. 28:1263–1269. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y and Pecquery R: Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Onco Rep. 20:971–977. 2008. | |
|
Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE and Thor AD: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E and Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:2088–2093. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Li T, Zhang Q, Zhang J, Yang G, Shao Z, Luo J, Fan M, Ni C, Wu Z and Hu X: Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway. BMC Cancer. 14:962014. View Article : Google Scholar : PubMed/NCBI | |
|
Green MR: Targeting targeted therapy. New Engl J Med. 350:2191–2193. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol. 23:2556–2568. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Krause DS and Van Etten RA: Tyrosine kinases as targets for cancer therapy. New Engl J Med. 353:172–187. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Flynn JF, Wong C and Wu JM: Anti-EGFR Therapy: Mechanism and advances in clinical efficacy in breast cancer. J Oncol. 2009:5269632009. View Article : Google Scholar : PubMed/NCBI | |
|
Agrawal A, Gutteridge E, Gee JM, Nicholson RI and Robertson JF: Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 12 Suppl 1:S135–S144. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Burness ML, Grushko TA and Olopade OI: Epidermal growth factor receptor in triple-negative and basal-like breast cancer: Promising clinical target or only a marker? Cancer J. 16:23–32. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Nahta R, Yuan LX, Zhang B, Kobayashi R and Esteva FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65:11118–11128. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shida D, Kitayama J, Mori K, Watanabe T and Nagawa H: Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res. 65:9159–9163. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Siziopikou KP and Cobleigh M: The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 16:104–107. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Siziopikou KP, Ariga R, Proussaloglou KE, Gattuso P and Cobleigh M: The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: A promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 12:360–362. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ishikawa M, Kitayama J and Nagawa H: Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 10:4325–4331. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Otvos L Jr, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD and Surmacz E: Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 47:1578–1584. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lethaby AE, Mason BH, Harvey VJ and Holdaway IM: Survival of women with node negative breast cancer in the Auckland region. N Z Med J. 109:330–333. 1996.PubMed/NCBI | |
|
Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, et al: Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience. Ann Oncol. 15:875–884. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med. 348:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Holmberg L, Lund E, Bergstrom R, Adami HO and Meirik O: Oral contraceptives and prognosis in breast cancer: Effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer. 30:351–354. 1994. View Article : Google Scholar | |
|
Coates RJ, Clark WS, Eley JW, Greenberg RS, Huguley CM Jr and Brown RL: Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst. 82:1684–1692. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Donegan WL, Hartz AJ and Rimm AA: The association of body weight with recurrent cancer of the breast. Cancer. 41:1590–1594. 1978. View Article : Google Scholar : PubMed/NCBI | |
|
den Tonkelaar I, de Waard F, Seidell JC and Fracheboud J: Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project. Breast Cancer Res Treat. 34:129–137. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Boyd NF, Campbell JE, Germanson T, Thomson DB, Sutherland DJ and Meakin JW: Body weight and prognosis in breast cancer. J Natl Cancer Ins. 67:785–789. 1981. | |
|
Williams G, Howell A and Jones M: The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. Br J Cancer. 58:631–634. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Niraula S, Ocana A, Ennis M and Goodwin PJ: Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. Breast Cancer Res Treat. 134:769–781. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, et al: Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 118:5937–5946. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen HL, Ding A and Wang ML: Impact of central obesity on prognostic outcome of triple negative breast cancer in Chinese women. Springerplus. 5:5942016. View Article : Google Scholar : PubMed/NCBI | |
|
Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, et al: Impact of body mass index on neoadjuvant treatment outcome: A pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 150:127–139. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Lu W, Zheng W, Gu K, Chen Z, Zheng Y and Shu XO: Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat. 122:823–833. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, et al: Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience. Ann Oncol. 15:875–884. 2004. View Article : Google Scholar : PubMed/NCBI |
